EFNB2 and neoplasm: Indeed, EFNB2 knock-down prior to implantation abrogated tumour initiation and treatment of pre-existing intracranial tumours with Ephrin-B2 blocking antibodies, under conditions that mimic human therapeutic paradigms, strongly reduced the growth and expansion of pre-formed tumours.